Milton José Max Rodríguez-Zúñiga1, Herney Andrés García-Perdomo2. 1. Dermatology Department, Hospital Nacional Daniel Alcides Carrion. Universidad Nacional Mayor de San Marcos, Lima, Peru. Electronic address: Milton_rz@hotmail.com. 2. Universidad del Valle and Universidad Libre, Cali, Colombia.
Abstract
BACKGROUND: Several studies have shown a relationship between psoriasis and metabolic syndrome (MS), but no meta-analysis has been restricted to studies that adjusted for confounders. OBJECTIVE: To determine the association between psoriasis and MS. METHODS: A systematic review and meta-analysis of observational studies on psoriasis and MS in adults was performed from MEDLINE, Scopus, SciELO, Google Scholar, Science Direct, and LILACS from inception to January 2016. We performed a random effects model meta-analysis for those studies reporting adjusted odds ratios (ORs) with 95% confidence intervals (CIs). The subgroup analysis was related to geographic location, diagnosis criteria and risk of bias. RESULTS: In all, 14 papers including a total of 25,042 patients with psoriasis were analyzed. We found that MS was present in 31.4% of patients with psoriasis (OR, 1.42; 95% CI, 1.28-1.65). Middle Eastern studies (in Israel, Turkey, and Lebanon) (OR, 1.76, 95% CI, 0.86-2.67) reported a greater risk for MS than European studies (in Germany, Italy, the United Kingdom, Norway, and Denmark) (OR, 1.40; 95% CI, 1.25-1.55). LIMITATIONS: Few adjusted studies existed, and there was inconsistency between publications. CONCLUSION: Because of the increased risk for MS, clinicians should consider screening patients with psoriasis for metabolic risk factors.
BACKGROUND: Several studies have shown a relationship between psoriasis and metabolic syndrome (MS), but no meta-analysis has been restricted to studies that adjusted for confounders. OBJECTIVE: To determine the association between psoriasis and MS. METHODS: A systematic review and meta-analysis of observational studies on psoriasis and MS in adults was performed from MEDLINE, Scopus, SciELO, Google Scholar, Science Direct, and LILACS from inception to January 2016. We performed a random effects model meta-analysis for those studies reporting adjusted odds ratios (ORs) with 95% confidence intervals (CIs). The subgroup analysis was related to geographic location, diagnosis criteria and risk of bias. RESULTS: In all, 14 papers including a total of 25,042 patients with psoriasis were analyzed. We found that MS was present in 31.4% of patients with psoriasis (OR, 1.42; 95% CI, 1.28-1.65). Middle Eastern studies (in Israel, Turkey, and Lebanon) (OR, 1.76, 95% CI, 0.86-2.67) reported a greater risk for MS than European studies (in Germany, Italy, the United Kingdom, Norway, and Denmark) (OR, 1.40; 95% CI, 1.25-1.55). LIMITATIONS: Few adjusted studies existed, and there was inconsistency between publications. CONCLUSION: Because of the increased risk for MS, clinicians should consider screening patients with psoriasis for metabolic risk factors.
Authors: Augusta Ortolan; Mariagrazia Lorenzin; Giulia Tadiotto; Francesco Paolo Russo; Francesca Oliviero; Mara Felicetti; Renata D'Incà; Marta Favero; Stefano Piaserico; Andrea Doria; Roberta Ramonda Journal: Clin Rheumatol Date: 2019-06-28 Impact factor: 2.980
Authors: Tanja Knopp; Tabea Bieler; Rebecca Jung; Julia Ringen; Michael Molitor; Annika Jurda; Thomas Münzel; Ari Waisman; Philip Wenzel; Susanne Helena Karbach; Johannes Wild Journal: Nutrients Date: 2021-05-31 Impact factor: 5.717